Commentary on the results and clinical implications of the PROactive study

Diabetes Care

Volumn 28, Issue 12, 2005, Pages 2965-2967

  Rizza, Robert ^a   Henry, Robert ^b   Kahn, Richard ^c  

^a MAYO CLINIC   (United States)

^b VA SAN DIEGO HEALTHCARE SYSTEM   (United States)

^c AMERICAN DIABETES ASSOCIATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLITAZONE DERIVATIVE; GLUCOSE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PIOGLITAZONE; 2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIDIABETIC AGENT; PLACEBO;

ALLOPATHY; CLINICAL STUDY; CLINICAL TRIAL; DRUG MECHANISM; GLUCOSE BLOOD LEVEL; HEART FAILURE; HUMAN; LIPID BLOOD LEVEL; MEDICAL DECISION MAKING; MEDICAL RESEARCH; METHODOLOGY; MORBIDITY; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; NOTE; VASCULAR DISEASE; ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; ORAL DRUG ADMINISTRATION; RANDOMIZED CONTROLLED TRIAL; REPRODUCIBILITY;

ADMINISTRATION, ORAL; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; HUMANS; HYPOGLYCEMIC AGENTS; PLACEBOS; REPRODUCIBILITY OF RESULTS; THIAZOLIDINEDIONES;

EID: 33644645475     PISSN: 01495992     EISSN: 01495992     Source Type: Journal    
DOI: 10.2337/diacare.28.12.2965     Document Type: Note

References (8)

1. Chilcott J, Tappenden P, Jones ML, Wight JP: A systematic review of the clinical effectiveness of pioglitazone in the treatment of type 2 diabetes mellitus. Clin Ther 23:1792-1823, 2001
2. Gegick C, Altheimer M: Thiazolidinediones: comparison of long-term effects on glycemic control and cardiovascular risk factors. Curr Med Res Opin 20:919-930, 2004
3. Yki-Jarvinen H: Thiazolidinediones. N Engl J Med 351:1106-1118, 2004
4. Del Prato S, Marchetti P: Targeting insulin resistance and beta-cell dysfunction: the role of thiazolidinediones. Diabetes Technol Ther 6:719-731, 2004
5. Charbonnel B, Dormandy J, Erdmann E, Massi-Benedetti M, Skene A, the PROactive Study Group: The Prospective Pioglitazone Clinical Trial in Macrovascular Events (PROactive): can pioglitazone reduce cardiovascular events in diabetes? Study design and baseline characteristics of 5238 patients. Diabetes Care 27:1647-1653, 2004
6. Dormandy JA, Charbonnel B, Eckland DJ, Erdmann E, Massi-Benedetti M, Moules IK, Skene AM, Tan MH, Lefebvre PJ, Murray GD, Standl E, Wilcox RG, Wilhelmsen L, Betteridge J, Birkeland K, Golay A, Heine RJ, Koranyi L, Laakso M, Mokan M, Norkus A, Pirags V, Podar T, Scheen A, Scherbaum W, Schernthaner G, Schmitz O, Skrha J, Smith U, Taton J, the PROactive Investigators: Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macro Vascular Events): a randomised controlled trial. Lancet 366:1279-1289, 2005
7. Nesto RW, Bell D, Bonow RO, Fonseca V, Grundy SM, Horton ES, Le Winter M, Porte D, Semenkovich CF, Smith S, Young LH, Kahn R, American Heart Association, American Diabetes Association: Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association: October 7, 2003. Circulation 108:2941-2948, 2003
8. Chiquette E, Ramirez G, Defronzo R: A meta-analysis comparing the effect of thiazolidinediones on cardiovascular risk factors. Arch Intern Med 164:2097-2104, 2004